1105039-88-0

Basic information

• Product Name: 1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• Synonyms: 1-[(4-methoxyphenyl)methyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-Pyrazole;1-[(4-methoxyphenyl)methyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole
• CAS NO: 1105039-88-0
• Molecular Formula: C₁₇H₂₃BN₂O₃
• Molecular Weight: 314.18712
• Mol File: 1105039-88-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1105039-88-0)
• EPA Substance Registry System: 1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1105039-88-0)

Safety Data

• Hazardous Substances Data: 1105039-88-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is used as a chemical intermediate for the synthesis of complex molecular structures, particularly in the development of new pharmaceutical compounds. Its reactivity in processes like Suzuki-Miyaura coupling allows for the creation of diverse and intricate molecules, which can be further utilized in drug discovery and design.
Used in Chemical Research:
In the field of chemical research, 1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole serves as a valuable compound for studying the properties and reactions of pyrazole rings and related structures. Its unique molecular composition enables researchers to explore various chemical reactions and mechanisms, contributing to the advancement of synthetic chemistry and material science.

Upstream product

• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1105039-89-1 2-bromo-6-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)pyridine 
• 1262849-05-7 2-(4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)thiazol-2-yloxy)pyridine 
• 1315566-72-3 5-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-3-chloro-1,2,4-thiadiazole 
• 1315566-73-4 N-(5-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-1,2,4-thiadiazol-3-yl)pyridin-2-amine 
• 1449669-00-4 2-ethyl-4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)aniline 
• 1449669-01-5 N-(2-ethyl-4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)phenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449669-02-6 N-(2-ethyl-4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)phenyl)-N, 1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1590410-77-7 C₂₄H₁₈F₃N₅O₃ 
• 1590410-76-6 C₃₁H₂₄F₃N₅O₃ 

Relevant articles and documents

AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

The invention provides certain amino-pyridine-containing compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R3, R4, R5, R6, and the subscript n are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS

The present application relates to novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors

The present invention relates to novel compounds of Formula (I), wherein M, P, X1, (A)m and (B)n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) wh

PREPARATION OF 4-AMINO-THIAZOLES AND 3-AMINO-1,2,4-THIADIAZOLES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of Formula (I), wherein M, P, X, A and (B)n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ("mGluR4") which are useful for the t

NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of Formula (I), wherein M, P, X1, X2, (A)m and (B)n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtyp

NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of Formula (I), wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4, M1, M2, M3, Am and Bn are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors-subtype 4 (?mGluR4?) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved

NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of Formula (I), wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4, M1, M2, M3, Am and